Dendritic cells generated in vivo by a chimeric hematopoietic growth factor, progenipoietin-4, demonstrate potent immunological function

Glenn Y. Ishioka, John Fikes, Mingsheng Qin, Carmen Gianfrani, Robert W. Chesnut, Larry E. Kahn, Philip Streeter, Susan L. Woulfe, Alessandro Sette

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Recently, a dual receptor agonist for human Flt3 and G-CSF receptors, progenipoietin-4 (ProGP-4), was shown to be highly effective in expanding DC in vivo. In this study, we examined the immunological activity of ProGP-4-generated dendritic cell (DC) in an HLA-A2.1 transgenic mouse system. ProGP-4 DC were found to be approximately equivalent in presenting a cytotoxic T lymphocyte (CTL) peptide to a CTL line in vitro compared with bone marrow (BM)-derived DC and > 20-fold more efficient than macrophages or B cells, and > 100-fold better than BM-DC, macrophages, or B cells at presenting PADRE, a universal helper T cell epitope, to a T cell clone. The heightened epitope presentation by ProGP-4 DC was paralleled in vivo inasmuch as a > 6-fold increase in CTL induction was observed compared with other APC populations following ex vivo loading with peptide. The in vitro and in vivo CTL responses stimulated by ProGP-4 DC could be further augmented by either culturing with tumor necrosis factor-α (TNF-α) or co-loading with PADRE. Collectively, our results indicate that peptide-loaded ProGP-4-generated DC demonstrate potent antigenicity and immunogenicity for CTL, making them an attractive component of epitope-based vaccines.

Original languageEnglish (US)
Pages (from-to)3710-3719
Number of pages10
JournalVaccine
Volume19
Issue number27
DOIs
StatePublished - Jun 14 2001
Externally publishedYes

Fingerprint

dendritic cells
Dendritic Cells
growth factors
Intercellular Signaling Peptides and Proteins
cytotoxic T-lymphocytes
Cytotoxic T-Lymphocytes
epitopes
peptides
Peptides
B-lymphocytes
Epitopes
macrophages
B-Lymphocytes
T-lymphocytes
Granulocyte Colony-Stimulating Factor Receptors
Macrophages
receptors
T-Lymphocyte Epitopes
tumor necrosis factors
bone marrow cells

Keywords

  • Cytotoxic T lymphocyte
  • Dendritic cell
  • Peptide

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Dendritic cells generated in vivo by a chimeric hematopoietic growth factor, progenipoietin-4, demonstrate potent immunological function. / Ishioka, Glenn Y.; Fikes, John; Qin, Mingsheng; Gianfrani, Carmen; Chesnut, Robert W.; Kahn, Larry E.; Streeter, Philip; Woulfe, Susan L.; Sette, Alessandro.

In: Vaccine, Vol. 19, No. 27, 14.06.2001, p. 3710-3719.

Research output: Contribution to journalArticle

Ishioka, GY, Fikes, J, Qin, M, Gianfrani, C, Chesnut, RW, Kahn, LE, Streeter, P, Woulfe, SL & Sette, A 2001, 'Dendritic cells generated in vivo by a chimeric hematopoietic growth factor, progenipoietin-4, demonstrate potent immunological function', Vaccine, vol. 19, no. 27, pp. 3710-3719. https://doi.org/10.1016/S0264-410X(01)00102-5
Ishioka, Glenn Y. ; Fikes, John ; Qin, Mingsheng ; Gianfrani, Carmen ; Chesnut, Robert W. ; Kahn, Larry E. ; Streeter, Philip ; Woulfe, Susan L. ; Sette, Alessandro. / Dendritic cells generated in vivo by a chimeric hematopoietic growth factor, progenipoietin-4, demonstrate potent immunological function. In: Vaccine. 2001 ; Vol. 19, No. 27. pp. 3710-3719.
@article{5eff163e329f49b3bab46a72c39394c4,
title = "Dendritic cells generated in vivo by a chimeric hematopoietic growth factor, progenipoietin-4, demonstrate potent immunological function",
abstract = "Recently, a dual receptor agonist for human Flt3 and G-CSF receptors, progenipoietin-4 (ProGP-4), was shown to be highly effective in expanding DC in vivo. In this study, we examined the immunological activity of ProGP-4-generated dendritic cell (DC) in an HLA-A2.1 transgenic mouse system. ProGP-4 DC were found to be approximately equivalent in presenting a cytotoxic T lymphocyte (CTL) peptide to a CTL line in vitro compared with bone marrow (BM)-derived DC and > 20-fold more efficient than macrophages or B cells, and > 100-fold better than BM-DC, macrophages, or B cells at presenting PADRE, a universal helper T cell epitope, to a T cell clone. The heightened epitope presentation by ProGP-4 DC was paralleled in vivo inasmuch as a > 6-fold increase in CTL induction was observed compared with other APC populations following ex vivo loading with peptide. The in vitro and in vivo CTL responses stimulated by ProGP-4 DC could be further augmented by either culturing with tumor necrosis factor-α (TNF-α) or co-loading with PADRE. Collectively, our results indicate that peptide-loaded ProGP-4-generated DC demonstrate potent antigenicity and immunogenicity for CTL, making them an attractive component of epitope-based vaccines.",
keywords = "Cytotoxic T lymphocyte, Dendritic cell, Peptide",
author = "Ishioka, {Glenn Y.} and John Fikes and Mingsheng Qin and Carmen Gianfrani and Chesnut, {Robert W.} and Kahn, {Larry E.} and Philip Streeter and Woulfe, {Susan L.} and Alessandro Sette",
year = "2001",
month = "6",
day = "14",
doi = "10.1016/S0264-410X(01)00102-5",
language = "English (US)",
volume = "19",
pages = "3710--3719",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "27",

}

TY - JOUR

T1 - Dendritic cells generated in vivo by a chimeric hematopoietic growth factor, progenipoietin-4, demonstrate potent immunological function

AU - Ishioka, Glenn Y.

AU - Fikes, John

AU - Qin, Mingsheng

AU - Gianfrani, Carmen

AU - Chesnut, Robert W.

AU - Kahn, Larry E.

AU - Streeter, Philip

AU - Woulfe, Susan L.

AU - Sette, Alessandro

PY - 2001/6/14

Y1 - 2001/6/14

N2 - Recently, a dual receptor agonist for human Flt3 and G-CSF receptors, progenipoietin-4 (ProGP-4), was shown to be highly effective in expanding DC in vivo. In this study, we examined the immunological activity of ProGP-4-generated dendritic cell (DC) in an HLA-A2.1 transgenic mouse system. ProGP-4 DC were found to be approximately equivalent in presenting a cytotoxic T lymphocyte (CTL) peptide to a CTL line in vitro compared with bone marrow (BM)-derived DC and > 20-fold more efficient than macrophages or B cells, and > 100-fold better than BM-DC, macrophages, or B cells at presenting PADRE, a universal helper T cell epitope, to a T cell clone. The heightened epitope presentation by ProGP-4 DC was paralleled in vivo inasmuch as a > 6-fold increase in CTL induction was observed compared with other APC populations following ex vivo loading with peptide. The in vitro and in vivo CTL responses stimulated by ProGP-4 DC could be further augmented by either culturing with tumor necrosis factor-α (TNF-α) or co-loading with PADRE. Collectively, our results indicate that peptide-loaded ProGP-4-generated DC demonstrate potent antigenicity and immunogenicity for CTL, making them an attractive component of epitope-based vaccines.

AB - Recently, a dual receptor agonist for human Flt3 and G-CSF receptors, progenipoietin-4 (ProGP-4), was shown to be highly effective in expanding DC in vivo. In this study, we examined the immunological activity of ProGP-4-generated dendritic cell (DC) in an HLA-A2.1 transgenic mouse system. ProGP-4 DC were found to be approximately equivalent in presenting a cytotoxic T lymphocyte (CTL) peptide to a CTL line in vitro compared with bone marrow (BM)-derived DC and > 20-fold more efficient than macrophages or B cells, and > 100-fold better than BM-DC, macrophages, or B cells at presenting PADRE, a universal helper T cell epitope, to a T cell clone. The heightened epitope presentation by ProGP-4 DC was paralleled in vivo inasmuch as a > 6-fold increase in CTL induction was observed compared with other APC populations following ex vivo loading with peptide. The in vitro and in vivo CTL responses stimulated by ProGP-4 DC could be further augmented by either culturing with tumor necrosis factor-α (TNF-α) or co-loading with PADRE. Collectively, our results indicate that peptide-loaded ProGP-4-generated DC demonstrate potent antigenicity and immunogenicity for CTL, making them an attractive component of epitope-based vaccines.

KW - Cytotoxic T lymphocyte

KW - Dendritic cell

KW - Peptide

UR - http://www.scopus.com/inward/record.url?scp=0035859305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035859305&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(01)00102-5

DO - 10.1016/S0264-410X(01)00102-5

M3 - Article

C2 - 11395205

AN - SCOPUS:0035859305

VL - 19

SP - 3710

EP - 3719

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 27

ER -